Business Wire

Moody’s Highlights its Ongoing Commitment to ESG

Share

Moody’s Corporation (NYSE:MCO) today highlighted recent developments underscoring its ongoing commitment to advancing environmental, social, and governance (ESG) initiatives.

“Moody’s is committed to working toward a sustainable future,” said Raymond McDaniel, President and CEO of Moody’s. “This commitment is evident through our strategic partnerships with prominent organizations that promote sustainability and social responsibility, our work toward implementing ESG principles in our own operations, and our growing capabilities in providing ESG-related thought leadership, assessments and data to market participants.”

Moody’s recent ESG-related activities have included:

United Nations Global Compact
On July 11, 2019, Lise Kingo, CEO and Executive Director of the United Nations Global Compact (UN Global Compact) met with Mr. McDaniel to welcome Moody’s as a Participant of the UN Global Compact. Launched in 2000 to encourage companies to engage in responsible business practices, the UN Global Compact is the largest corporate sustainability initiative in the world with over 9,500 business and 3,000 non-business signatories. As part of its membership, Moody’s will submit an annual progress report including a description of practical actions the company has taken to enhance its sustainability efforts.

Principles for Responsible Investment
Moody’s recently became a signatory to the Principles for Responsible Investment (PRI), an international association of asset owners, investment managers, and service providers working toward a more sustainable global financial system through the incorporation of ESG factors into investment decisions. This builds on Moody’s 2016 signing of PRI’s Statement on ESG in Credit Ratings, part of an initiative to enhance the transparent and systematic integration of ESG factors in credit risk analysis. As a PRI member, Moody’s joins a network of over 2,200 organizations in endorsing PRI’s six core principles related to acting in the best long-term interest of investors and incorporating ESG issues into investment and disclosure practices.

"Moody's has long recognized the importance of considering ESG factors in credit decisions," said Fiona Reynolds, PRI CEO. "By joining the PRI and the UN Global Compact, they are further underscoring their commitment to sustainability, a move which we welcome."

Task Force on Climate-related Financial Disclosures Report
On July 10, 2019, Moody’s released its annual report in response to the Task Force on Climate-related Financial Disclosures (TCFD), an organization established by the Financial Stability Board to promote more informed financial decisions and to improve understanding of exposure to climate-related risk. Moody’s report mirrors the TCFD’s recommendations for climate disclosure and includes information on operations structured around four thematic areas – governance, strategy, risk management, and metrics and targets.

Moody’s Acquisitions of Four Twenty Seven and Vigeo Eiris
Moody’s recently announced the acquisition of a majority stake in Four Twenty Seven, Inc., a leading provider of data, intelligence and analysis related to physical climate risks. Four Twenty Seven’s climate risk scores and portfolio analytics cover over 2,000 listed companies, one million global corporate facilities, 320 REITS and 3,000 US counties, and are used by asset owners, asset managers, banks and corporations.

The acquisition of Four Twenty Seven, Inc., complements Moody’s recent announcement of a majority stake in Vigeo Eiris, a leading Paris-based provider of ESG research, data and assessments. Together, these acquisitions broaden Moody’s growing platform of risk assessment capabilities and underscore its work to advance global standards for assessing environmental and climate risk factors. For more information about Moody’s approach to ESG, visit https://esg.moodys.io/.

About Moody’s Corporation
Moody's is an essential component of the global capital markets, providing credit ratings, research, tools and analysis that contribute to transparent and integrated financial markets. Moody’s Corporation (NYSE:MCO) is the parent company of Moody's Investors Service, which provides credit ratings and research covering debt instruments and securities, and Moody's Analytics, which offers leading-edge software, advisory services and research for credit and economic analysis and financial risk management. The corporation, which reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 44 countries. Further information is available at https://www.moodys.com/.

Moody’s believes in a world where more people have access to opportunity, and where everyone has what they need to grow and thrive. We are committed to opening the door to a better future through our global corporate social responsibility programs empowering people around the world with the knowledge, resources and confidence they need to succeed. For more information visit moodys.com/csr.

Contact information

SALLI SCHWARTZ
Moody’s Investor Relations
+1 212-553-4862
sallilyn.schwartz@moodys.com 

OR

MICHAEL ADLER
Corporate Communications 
+1-212-553-4667
michael.adler@moodys.com 

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing